The abstract is read at the publisher; the summary is JClub's.
NKTR-255 plus ROR1-targeting CAR T therapy in mouse ROR1+ lung adenocarcinoma boosts tumor-infiltrating CAR T function and completely eliminates ROR1+ tumors.
- Why it matters: Solid tumors limit CAR T persistence and function, and antigen heterogeneity can enable escape; boosting both CAR T activity and endogenous antitumor immunity may be needed for durable control.
- What they did: In mouse ROR1+ lung adenocarcinoma models, NKTR-255 (polymer-conjugated IL-15 with extended half-life) was combined with ROR1 CAR T cells and compared with either treatment alone and with IL-15-armored CAR T cells.
- The result: The combination increased endogenous tumor-specific T cells retaining a PD-1+Tcf1+ stem-like phenotype, improved survival, and showed tumor control requiring both CAR T cells and endogenous T cells, while systemic NKTR-255 outperformed IL-15-armored CAR T cells in accumulation and reduced terminal differentiation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.